Outlook Therapeutics (OTLK) Year-over-year earnings per share growth for the last twelve months

Outlook Therapeutics Inc (OTLK) - corporate logo

Outlook Therapeutics is scaling the production of ophthalmological agents, aiming for global expansion with minimal costs. In the long term, the business relies on the market launch of FDA-approved bevacizumab for the treatment of AMD. Quarterly earnings per share dynamics visualize this potential, with 90.00 showing the level of this metric. Current growth is constrained by a dependence on external contract manufacturing.

Outlook Therapeutics Inc (OTLK) Earnings per share growth in annualized terms for the last twelve months: for the period 07/04/2022 - 11/16/2026

outlooktherapeutics.com - analytical breakdowns and key metrics (OTLK)

Fundamental valuation:Outlook Therapeutics
Finished products of Outlook Therapeutics

For the biopharmaceutical sector of Outlook Therapeutics (OTLK), where the registration of Lytenava is complicated by FDA rejections and a liquidity shortage, profit dynamics become a critical marker for survival. Analyzing the quarterly growth rate of net income per share allows for an assessment of the pace of yield changes relative to previous periods, determining the business's margin of safety and the risk of capital freeze should operational momentum fade.

Analysis of competing companies

Alcon Corp (ALC) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Bausch Health (BLCO)|Year-over-year earnings per share growth for the last twelve months glaukos.com|Apellis Pharmaceuticals (APLS) - Year-over-year net earnings per share change for the last twelve months|Quarterly EPS earnings growth BLTE|OCUL - Earnings per share growth in annualized terms for the last twelve months|Quarterly EPS earnings growth HROW (Harrow Inc)|Year-over-year net earnings per share change for the last twelve months Viridian Corp (VRDN)|LENZ - Year-over-year earnings per share growth for the last twelve months|Oculis - Year-over-year earnings per share growth rate for the last twelve months|EyePoint Pharmaceuticals (EYPT) - Year-over-year earnings per share growth for the last twelve months|Kodiak Sciences Inc (KOD) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months ALDX|KALA: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth IRD|OKYO: Year-over-year net earnings per share trend for the last twelve months|Year-over-year earnings per share growth for the last twelve months Adverum Biotechnologies ADVM|Year-over-year net earnings per share change for the last twelve months Clearside Biomedical, Inc. (CLSD)|NBY - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per one share growth for the last 12 months KPRX (kiorapharma.com)|Alimera Sciences (ALIM) - Year-over-year earnings per share growth for the last twelve months|Eyenovia Inc. - Year-over-year earnings per one share growth for the last 12 months|GHSI (Guardion Health Sciences) - Quarterly EPS earnings growth|Ocuphire Pharma - Year-over-year net earnings per share trend for the last twelve months|Year-over-year net earnings per share growth for the last 12 months OPT (Opthea)